<i>De novo</i> CD5-positive diffuse large B-cell lymphoma with leukemic dissemination diagnosed by immunohistochemical examinations of bone marrow clot sections

DOI Web Site PubMed 1 Citations 13 References

Bibliographic Information

Other Title
  • 骨髄クロットの免疫組織化学検査により確定診断した白血化<i>de novo</i> CD5陽性びまん性大細胞型B細胞リンパ腫
  • 症例 骨髄クロットの免疫組織化学検査により確定診断した白血化de novo CD5陽性びまん性大細胞型B細胞リンパ腫
  • ショウレイ コツズイ クロット ノ メンエキ ソシキ カガク ケンサ ニ ヨリ カクテイ シンダン シタ ハッケツカ de novo CD5 ヨウセイビマンセイ ダイ サイボウガタ B サイボウ リンパ シュ

Search this article

Description

A 61-year-old male visited his doctor in October 2000 because of a high fever. Laboratory examination revealed leukocytosis with blast-like cells and thrombocytopenia. He was referred and admitted to our hospital in November 2000. Although he had mild splenomegaly, he had no lymphadenopathy on the first admission. The white blood cell count was 10,520/μl with 45% blast-like cells and the platelet count was 51×103/μl. Bone marrow aspiration revealed 82% blast-like cells, which were positive for CD5, CD10, CD13, CD19, and CD20. Immunohistochemistry of the bone marrow clot sections revealed blast-like cells were positive for CD5, but negative for TdT, CD23 and cyclin D1. We diagnosed the patient as having de novo CD5-positive diffuse large B-cell lymphoma (DLBCL) with leukemic dissemination. He obtained a complete remission after two courses of CHOP therapy. The third chemotherapy was postponed because of strangulation of the intestine. He relapsed and died in spite of the third chemotherapy. CD5-positive DLBCL is one of the established disease entities that requires an appropriate therapy regimen because it is characterized by elderly onset, extranodal involvement, and a poorer prognosis.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 43 (10), 943-948, 2002

    The Japanese Society of Hematology

Citations (1)*help

See more

References(13)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top